Close Menu

NEW YORK – Fluidigm reported after the close of the market on Thursday that its second quarter revenues increased 7 percent year over year on continued strength in its mass cytometry product portfolio.

Despite the increased revenues, the market reacted negatively as Fluidigm missed top-line estimates and provided soft third quarter guidance on continued weakness in its microfluidics product sales. In Friday morning trading on the Nasdaq, Fluidigm's shares were down around 38 percent to $7.52.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.

Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.